Article Text

Effect of latanoprost on intraocular pressure in patients with glaucoma on maximal tolerated medical treatment
  1. AUGUSTO AZUARA-BLANCO,
  2. L JAY KATZ,
  3. GEORGE L SPAETH,
  4. RICHARD P WILSON,
  5. MARLENE R MOSTER,
  6. KELLY J FLARTEY
  1. Glaucoma Service, Wills Eye Hospital, Jefferson Medical College, 900 Walnut Street, Philadelphia, PA 19107, USA.
  1. L Jay Katz, MD.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Editor,—Latanoprost 0.005% is a prostaglandin analogue that causes reduction of the intraocular pressure (IOP) by increasing the uveoscleral outflow of aqueous humour through the ciliary muscle region to the suprachoroidal space and the episcleral veins.12 Initial studies on latanoprost demonstrated reductions of 20% to 40% in the IOP of normotensive volunteers, patients with ocular hypertension, and glaucoma patients.3-10 The efficacy of latanoprost 0.005% in lowering the intraocular pressure (IOP) in different glaucoma populations, especially when added to anti-glaucoma medications already being used, …

View Full Text